ARCHIVES

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 17 | May 2, 2008

Download PDF Visit The Full Archive

Related Articles

As MD Anderson Targets Eight Cancers, Detailed War Plan Remains Under Wraps

September 21, 2012

Fisher Seeks Damages Under Privacy Act; NIH Consents To Remove Database Flags

March 10, 1995

FDA Approves Velcade For Treatment Of Refractory Multiple Myeloma

May 30, 2003

NCI Board of Scientific Advisors also approved a new SBIR grant program for research on circulating cells in cancer detection.

March 26, 2004

Dial Access Offers Caner Consultation Services

February 21, 1975

Clinical Trials Approved By NCI Last Month Are Listed

January 25, 2002